Topic
1 story, newest first.
AstraZeneca has released full results from two late-stage trials of its experimental COPD drug, tozorakimab. The data indicates the drug reduced flare-ups by up to 43% in various patient groups and has led AstraZeneca to raise its peak annual sales forecast for the drug to over $5 billion.
